Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. FDA-approved antibiotic with the power of a penem in a novel oral formulation, offering a vital alternative in treating uncomplicated urinary tract infections DUBLIN and CHICAGO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the U.S. commercial launch of ™ (sulopenem etzadroxil and...
Dorchester Minerals, L.P. Announces Second Quarter Results DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP) announced today the Partnership’s net income for the quarter ended June 30, 2025 of $12,347,000, or $0.25 per common unit. A comparison of the Partnership’s consolidated results for the quarters ended June 30, 2025 and 2024 are set forth below: Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024Operating Revenues$32,395,000 $37,360,000 $75,559,000 $68,339,000Net Income$12,347,000 $23,628,000 $29,989,00...
Iterum Therapeutics Reports Second Quarter 2025 Financial Results -- Launch of ORLYNVAHTM Expected August 2025— --Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the second quarter ended June 30, 2025. "We are on track to launch ORLYNVAH™ this month for th...
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 DUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its second quarter 2025 financial results before the open of the U.S. financial markets on Tuesday, August 5, 2025. Management will host a conference call at 8:30 a.m. ET that ...
Dorchester Minerals, L.P. Announces Its Second Quarter Distribution DALLAS, July 24, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s second quarter 2025 cash distribution. The distribution of $0.620216 per common unit represents activity for the three-month period ended June 30, 2025 and is payable on August 14, 2025 to common unitholders of record as of August 4, 2025. Cash receipts attributable to the Partnership’s Royalty Properties during the second quarter totaled approximately $26.6 million. Approximately 73% of these receipts ref...
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced that it has granted a non-statutory share option to purchase an aggregate of 200,000 ordinary shares of Iterum to Christine Coyne, Iterum’s newly appointed Chief Commercial Officer. This grant was awarded pursuant to the Nasdaq inducemen...
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiotics to address infections caused by multi-drug resistant pathogens, today announced the appointment of Christine Coyne to the newly created position of Chief Commercial Officer. In this role, Ms. Coyne will lead all commercial efforts for Iterum, including the upcoming launch of ORLYNVAH™ in the Un...
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence 9.2% of Patients in REASSURE’s Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics DUBLIN and CHICAGO, June 25, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that NEJM Evidence published results from its REASSURE (REnewed ASsessment of Sul...
Iterum Therapeutics Announces Partnership for Commercialization Services U.S. Commercial Launch of ORLYNVAHTM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that it entered into a Product Commercialization Agreement (th...
Dorchester Minerals, L.P. Announces Retirement and Appointment to the Board of Managers DALLAS, May 19, 2025 (GLOBE NEWSWIRE) -- Dorchester Minerals, L.P. (the “Partnership”) (NASDAQ-DMLP). As previously announced, Ron Trout retired as an Independent Manager of the Partnership after the conclusion of his term, which ended immediately following the 2025 Annual Meeting. Casey McManemin, Chairman of the Board, stated “I would like to thank Ron for 17 years of dedicated service to the Board of Managers. His business acumen and insights have made a meaningful contribution to the Board.” In ...
Iterum Therapeutics Announces Extension of Term of Promissory Note DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported that Pfizer Inc. (“Pfizer”) has agreed to extend the term for payment of the regulatory milestone payment of $20.0 million until October 25, 2029. “We are very pleased to announce that Pfizer has agreed to extend th...
Iterum Therapeutics Reports First Quarter 2025 Financial Results --Preparing for Potential Launch of ORLYNVAHTM by Q4 2025-- --Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the first quarter ended March 31, 2025. “Based on pre-commercial...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.